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Vascular Endothelial Growth Factor (VEGF) is a po-
tent mitogen for vascular endothelial cells that has been
implicated in tumor neovascularization. We show that,
in hamster fibroblasts (CCL39 cells), VEGF mRNAs are
expressed at low levels in serum-deprived or exponen-
tially growing cells, whereas it is rapidly induced after
stimulation of quiescent cells with serum. CCL39 deriv-
atives, transformed with Polyoma virus or with active
members of the p42/p44 mitogen-activated protein
(MAP) kinase pathway, Gly/Val point mutant of Ras at
position 12 (Ras-Val12), MKK1 in which Ser218 and Ser222
were mutated to Asp (MKK1-SS/DD)), express very high
levels of VEGF mRNA. To analyze the contribution of the
p42/p44MAP kinase in this induction, we used the
CCL39-derived cell line (Raf-1:ER) expressing an estra-
diol-activable Raf-1. We show a time and an estradiol
dose-dependent up-regulation of VEGF mRNA clearly
detectable after 2 h of stimulation. The induction of
VEGF mRNA in response to conditioned activation of
Raf-1 is reverted by an inhibitor of MKK1, PD 098059,
highlighting a specific role for the p42/p44 MAP kinase
pathway in VEGF expression. Interestingly, hypoxia has
an additive effect on VEGF induction in CCL39 cells
stimulated by serum or in Raf-1:ER cells stimulated by
estradiol. In contrast to VEGF, the isoforms VEGF-B and
VEGF-C are poorly regulated by growth and oncogenic
factors. We have identified a GC-rich region of the VEGF
promoter between 288 and 266 base pairs which con-
tains all the elements responsible of its up-regulation by
constitutive active Ras or MKK1-SS/DD. By mutation of
the putative binding sites and electrophoretic mobility
supershift experiments, we showed that the GC-rich re-
gion constitutively binds Sp1 and AP-2 transcription
factors. Furthermore, following activation of the p42/
p44 MAP kinase module, the binding of Sp1 and AP-2 is
increased in the complexes formed in this region of the
promoter. Altogether, these data suggest that hypoxia
and p42/p44 MAP kinase independently play a key role
in the regulation of the VEGF expression.
Angiogenesis is a fundamental physiological process by
which new blood vessels are formed (1). One of the most widely
described mechanisms controlling neovascularization associ-
ated with pathological processes (2) is the increased secretion
by the “stressed cells” (inflammation, psoriasis) or nutrient-
deprived tumor cells of multiple growth factors (3–7) and cyto-
kines (8, 9). Among growth factors, two major classes have been
characterized: acid and basic FGF of the FGF family (3, 4) and
Vascular Endothelial Growth Factor, VEGF,1 a new family of
secreted growth factors structurally related to PDGF (40%
homology at the amino acid level) (5–7). VEGF, also described
as a permeability factor, stimulates endothelial cell migration
and proliferation in vitro and has angiogenic activity in vivo
(10, 11). Different isoforms of 121, 165, 189, and 206 amino
acids resulted from alternative splicing of the same gene (12).
Many tissues and cell types express VEGF mRNA, especially
tissues which are highly vascularized in addition to tumor-
derived cell lines (13). Stimulation of serum-deprived NIH 3T3
cells by PDGF also results in VEGF induction in a Ras- and
Raf-dependent manner (14). Deprivation of oxygen during cell
culture, which mimics the necrotic hypoxic regions in solid
tumors, induces VEGF mRNA expression by both an increase
in the rate of transcription but also by stabilization of its
mRNA (15–17). Considering the key role played by VEGF in
the control of neovascularization (6, 7), it is of primary impor-
tance to decipher the growth factor-activated signaling path-
ways involved in controlling its expression.
In the present report, we have compared the expression of
VEGF in resting, serum-stimulated, or oncogenically trans-
formed CCL39 fibroblasts (18, 19). Exploiting a CCL39-derived
cell line in which Raf-1 can be rapidly activated by estradiol
(Raf-1:ER) (20–22), we demonstrated that the p42/p44 MAP
kinase cascade is critical in the control of VEGF expression. To
further characterize the effect of constitutively active Ras or
MKK1 on the VEGF expression, we have assayed different
constructs of the VEGF promoter in order to define cis-active
regions sufficient to promote regulation of VEGF transcription
by members of the p42/p44 MAP kinase module. By electro-
phoretic mobility assays (EMSAs) and supershift assays, we
also defined transcription factors whose binding on the VEGF
promoter is regulated through p42/p44 MAP kinase cascade.
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EXPERIMENTAL PROCEDURES
Cell Culture—The established Chinese hamster lung fibroblast line
CCL39 (American Type Culture Collection), their derivatives PS120
and PS200, which lack NHE1 antiporter activity (23), and correspond-
ing transfected cells were cultivated in Dulbecco’s modified Eagle’s
medium (Life Technologies, Inc.) containing 7.5% fetal calf serum, pen-
icillin (50 units/ml), and streptomycin sulfate (50 mg/ml). Growth-ar-
rested cells were obtained by total deprivation of serum for 16–24 h.
Raf-1:ER cells (clone 18 or 19) are a derivative of CCL39, and they
stably expressed a fusion protein between the catalytic domain of Raf-1
and the hormone binding domain of the estrogen receptor (20–22).
These cells were cultivated in the same medium described above with-
out phenol red to reduce the basal activity of the Raf-1:ER construct.
Hypoxia was generated by placing the cells in hermetic jars together
with the Gas Pak Plus system from Becton Dickinson. In this system,
hydrogen generated from sodium borohydride following the addition of
water combines with the oxygen present in the jar in the presence of
palladium catalyst to form water. Oxygen deprivation is almost com-
plete after 1 h of incubation. Approximately 4–10% carbon dioxide is
generated during this oxygen removal. Thus, cells are cultivated in the
same bicarbonate-buffered medium.
Materials—Restriction and DNA modifying enzymes were obtained
from New England Biolabs or from Eurogentec, Liège, Belgium.
[a-32P]dCTP, [a-33P]dATP were from ICN. Synthetic oligonucleotides
were from Eurogentec, Liège, Belgium.
Production of VEGF, VEGF-B, and VEGF-C Probes—First strand
cDNA was synthesized from 1 mg of CCL39 poly(A)1 RNA using avian
myeloblastosis virus reverse transcriptase with oligo(dT) primer. This
material was used as template for polymerase chain reaction (PCR)
amplification. The following oligonucleotides derived, respectively, from
human VEGF, mouse VEGF-B (24), human VEGF-C (25) sequences,
were synthesized and used as primers for the PCR reaction: 59-AT-
GAACTTTCTGCTGTCTTGGG-39 and 59-CCGCCTCGGCTTGTCACA-
TCTGC-39; 59-ATGAGCCCCCTGCTCCGTCGCCTG-39 and 59-CTTTC-
GCGGCTTCCGGCACC-39; and 59-ATGACTGTACTCTACCCAGAATA-
TTG-39 and 59-GCTCATTTGTGGTCTTTTC-39. An aliquot of cDNA was
amplified in a 50-ml reaction volume with 200 ng of each primer, 200 mM
dNTPs, and 2.5 units of GoldstarTaq DNA polymerase (Eurogentec) or
ampli-Taq from Boehringer Mannheim in a buffer containing 10 mM
Tris-HCl, pH 8.3, 50 mM KCl, 1.5 mM MgCl2, and 0.001% gelatin. The
PCR amplification was performed in a DNA thermal cycler (Biotechnia)
using the following parameters: 30 s at 95 °C, 1 min at 55 °C, and 1 min
at 72 °C for 30 cycles followed by an extra cycle with a 10-min extension
step at 72 °C. Expected fragments of approximately 600 and 550 bp for
VEGF, 600 bp for VEGF-B, and 1200 bp for VEGF-C were obtained.
These fragments were purified on agarose gels and used as probes for
Northern analysis. The fragments were also cloned in the pTAG vector
using the manufacturer protocol (R & D Systems Europe Ltd.). The
different inserts were sequenced using a Universal or T7 primer or
specific oligonucleotides for each sequence. No specific problems related
to low abundance of mRNA were encountered during the cloning of
VEGF-B and VEGF-C from Chinese hamster lung fibroblasts even
though lung is a tissue where they represent poorly abundant mRNA
species (24, 25). The high percentage of homology (98%) with Chinese
hamster, mouse, or human homologs has allowed us to use both mouse
and hamster VEGF probes for Northern experiments.
Transient Transfection and Luciferase Assay—CCL39 cells in 12-well
dishes (105 cells/well) were transiently transfected by CaPO4 precipita-
tion with the indicated plasmids (250 ng/well of the reporter plasmid,
200 ng of expression vector, and 100 ng of CMV b-galactosidase as a
control of transfection efficiency). Sixteen hours after addition of DNA,
the cells were washed twice with PBS and incubated with Dulbecco’s
modified Eagle’s medium with or without 7.5% fetal calf serum. Two
days later, the cells were washed with cold PBS, and luciferase assays
were performed as follows (Promega protocols and applications guide).
Cells were lysed in lysis buffer (25 mM Tris-phosphate, pH 7.8, 2 mM
DTT, 2 mM 1, 2-diaminocyclohexane-N,N,N9,N9-tetraacetic acid, 10%
glycerol, and 1% Triton X-100) for 15 min at room temperature, and the
lysate was cleared by centrifugation. The assay of luciferase activity
was performed in a chemioluminometer in a buffer containing 20 mM
Tricine, 1.07 mM (MgCO3)Mg(OH)2, 5H2O, 2.67 mM MgSO4, 0.1 mM
EDTA, 33.3 mM DTT, 270 mM coenzyme A, 470 mM luciferine, and 530
mM ATP. Protein concentration was measured using the bicinchonic
acid (BCA) protein assay kit (Pierce) with bovine serum albumin as
standard.
Preparation of RNA—Cells were washed in ice-cold PBS and lysed in
the “RNA Insta-Pure” buffer from Eurogentec. The supernatant was
cleared by centrifugation, ethanol precipitated, and resuspended in
sterile water.
Promoter Construction and Mutagenesis Experiments—Dr. Werner
Risau kindly provided the human VEGF promoter gene construct
(21176/154) (16) cloned in the pGL2 basic vector from Promega. Con-
struct 288/154 was obtained by cutting the above vector by SmaI (one
site in the vector and one site at position 288 of the promoter) and
re-ligating. Construct 227/154 was obtained by subcloning a DraI/NheI
fragment within the SmaI/NheI sites of pGL2 basic. The 266/154 and
252/154 constructs were generated by PCR by using oligo 1, 59-
GCGGGTACC(T)CCCGGCGGGGCGG-39; and oligo 2, 59-GCGGGTAC-
C(A)GCCATGCGCCCCC-39, respectively. Bases shown in bold corre-
spond to positions 266 and 252, respectively. At their 59 ends, both
oligos contain the KpnI restriction site. They were used in a PCR
reaction with oligo 3, 59-CTTTATGTTTTTGGCGTCTTCCA-39, which
corresponds to a sequence within the vector at the 39 end of the pro-
moter. The amplified fragments were digested with KpnI and NheI and
inserted into the pGL2 basic vector (Promega). We mutated the AP-2
site, both Sp1 sites or all three binding sites by the PCR method (26, 27).
The following oligonucleotides were chosen: oligo 4, 59-TGTATCTTAT-
GGTACTGTAACTG-39; oligo 5, 59-GGGGCGGGCC(TA)GGGCGGGG-
39; oligo 6, 59-CCCCGCCC(TA)GGCCCGCCCC-39; oligo 7, 59-GCCCC-
CCGGG(AA)GGGCCGGGG(AA)GGGGTCCG-39; oligo 8, 59-CGGACC-
CC(TT)CCCCGGCCC(TT)CCCGGGGGGC-39; oligo 9, 59-GGG(AA)GG-
CC(TA)GG(AA)GGGGTC-39; and oligo 10, 59-GAACCCC(TT)CC(TA)G-
GCCC(TT)CCC-39. Oligo 4 corresponds to a sequence within the vector
at the 59 end of the promoter. For oligos 5, 6, 7, 8, 9, and 10, bases shown
in bold indicate those modified in relation to the wild type sequence
(oligos 5 and 6 for AP-2 mutation; oligos 7 and 8 for mutation of both
Sp1 sites; oligos 9 and 10 for mutation of the AP-2 site and both Sp1
sites; see also Fig. 6a). After obtention of the –1176/154 mutated const-
ructs, we digested them with SmaI to obtain the corresponding
288/154 constructs. For the triple mutant, we used the construct
21176/154 that was mutated for both Sp1 binding sites and oligos 9
and 10 for mutation of the remaining AP-2 binding site before digestion
with SmaI to obtain the 288/154 construct. The presence of the mut-
ations were verified by gel sequencing.
Preparation of Nuclear Extracts and Gel Mobility Shift Assays—
Confluent Raf-1:ER cells cultures were serum-starved overnight fol-
lowed by stimulation with or without estradiol (1 mM) for 3 h. Nuclei
were isolated by the isotonic/Nonidet P-40 procedure: cells were resus-
pended in HNB (0.5 M sucrose, 15 mM Tris, pH 7.5, 60 mM KCl, 0.25 mM
EDTA, pH 8, 0.125 mM EGTA, 0.5 mM spermidine, 1 mM DTT, 0.1 mM
phenylmethylsulfonyl fluoride, 5 mg/ml aprotinin, 5 mg/ml pepstatin, 5
mg/ml leupeptin, 50 mM NaF, 40 mM b-glycerophosphate, 200 mM pa-
ranitrophenylphosphate, 0.2 mM orthovanadate) and homogenized in
HNB containing 0.2% Nonidet P-40. Nuclei were recovered by centrif-
ugation at 3000 rpm and rinsed in HNB alone. Nuclear extracts were
then prepared by the method described by Dignam et al. (28). The probe
was synthesized to span the region of the human VEGF promoter
comprised between the 288 and 266 bp: 59-TTTCCGGGGCGGGC-
CGGGGGCGGGGTAT-39 (random sequences added to the wild type
sequence are shown in italic letters). Protruding 59 ends were filled in
with (exo-) Klenow fragment (from Stratagene) and [a-32P]-dCTP and
dATP. The DNA binding reaction was performed for 15 min at room
temperature in a final volume of 15 ml. A first volume of 7.5 ml was
prepared containing 5 mg of nuclear extracts, 0.75 mg/ml poly(dI:dC)
(Sigma), dialysis buffer (20 mM Hepes, pH 7.9, 60 mM KCl, 20% glycerol,
0.25 mM EDTA, 0.125 mM EGTA, 1 mM DTT), protease and phosphatase
inhibitors) (see HNB). The residual 7.5 ml was comprised of 90 fmol of
labeled probe (1–2.105 cpm), with or without excess (60–600-fold) of
unlabeled probe, and with or without excess (100-fold) of Sp1 or AP-2
consensus oligonucleotides (Promega): Sp1, 59-ATTCGATCGGGGCGG-
GGCGAGC-39 and 39-TAAGCTAGCCCCGCCCCGCTCG-59; AP-2, 59-G-
ATCGAACTGACCGCCCGCGGCCCGT-39 and 39-CTAGCTTGACTGG-
CGGGCGCCGGGCA-59.
The competitors were added 15 min before addition of the probe.
Supershift assays were performed with 2.5–3 mg of nuclear extracts.
The Sp1 (PEP-2) and AP-2a (C-18) antibodies were purchased from
Santa Cruz Biotechnology. 0.2 mg of Sp1 antibody was incubated 30 min
at 4 °C after addition of the probe, whereas 1 mg of AP-2a antibody was
added 30 min before the addition of the probe. Electrophoresis was
performed on a 4% polyacrylamide (30 acrylamide, 0.8 bisacrylamide)
gel, in 0.53 TBE (44.5 mM Tris, 44.5 mM boric acid, 1 mM EDTA), for
4–5 h at 280–300 V/10–12 mA .
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RESULTS
VEGF mRNA but Not VEGF-B and VEGF-C Are Regulated
by Growth and Oncogenic Factors in CCL39 Cells—Under nor-
moxic conditions, exponentially growing CCL39 or its deriva-
tive PS 200 Chinese hamster lung fibroblasts express barely
detectable levels of VEGF mRNA (right lanes of Fig. 1). Serum
stimulation of growth-arrested CCL39 (data not shown) or PS
200 cells (left lanes of Fig. 1) triggers the induction of VEGF
mRNA. However, this expression is strongly elevated in cells
transformed either with Polyoma virus, Ha-Ras (Ras-Val12)
(18) or a constitutive active form of MAP kinase kinase (MKK1-
SS/DD) (19). At least four isoforms that correspond to the
spliced variants described (12) detectably hybridize to a mouse
VEGF probe. Fig. 1 shows that, in the Polyoma virus, Ha-Ras
and MKK1-SS/DD transformed cells, the different VEGF
mRNA isoforms are expressed at a level approximately 10-fold
superior to that of control cells. This overexpression is partic-
ularly prominent for the clone 5c that overexpressed Ha-Ras
(18). For each of the cell lines tested, FCS was able to increase
the amount of VEGF mRNA, although in transformed cells the
basal level was extremely elevated. However, this is not the
case for cells expressing MKK1-SS/DD and isolated from a
tumor produced in nude mice (T.MKK1-SS/DD). Interestingly,
these cells were shown to be fully independent of serum growth
factors (19). This could explain the inability of serum to further
modify the elevated level of VEGF mRNA in these tumor cells.
In the different cell lines tested, the other members of the
VEGF family, VEGF-B and VEGF-C, are constitutively ex-
pressed showing that both genes are not tightly regulated via
growth or oncogenic factors even if VEGF-C seems to be up-
regulated in MKK1-SS/DD transformed cells.
p42/p44 MAP Kinase Cascade Specifically Induces VEGF
mRNA Expression in Raf-1:ER-expressing Cells—To further
FIG. 2. Regulation of expression of VEGF in Raf-1:ER express-
ing cells. a, 20 mg of RNA isolated from quiescent or estradiol-stimu-
lated Raf-1:ER cells (1 mM) for the times indicated were analyzed by
Northern blot for expression of VEGF, VEGF-B, and VEGF-C. As de-
scribed in Fig. 1, 28 S ribosomal RNA is shown as loading control. b,
Raf-1:ER cells were serum-deprived for 16 h and then stimulated with
estradiol for 4 h at different concentrations (0, 0.1, 1, 10, 100, 1000 nM)
in the presence or absence of oxygen (see “Experimental Procedures”).
20 mg of RNA were analyzed by Northern blot. The specific signal for
VEGF was quantified by using a phosphoimager. c, the MKK1 inhibitor
PD 098059 inhibits the estradiol induction of VEGF mRNA. Raf-1:ER
cells were serum-deprived for 16 h and then stimulated or not with
estradiol (1 mM) for 4 h in the presence (1) or absence (–) of PD 098059,
100 mM, and in the presence or absence of oxygen. Levels of VEGF
mRNA were quantitated using a phosphoimager. 18 S ribosomal RNA is
shown as loading control.
FIG. 1. Expression of VEGF in resting, serum-stimulated, and
transformed cells. 20 mg of total RNA isolated from cells transformed
by Ras-Val12, Polyoma virus (Py), constitutively active MAP kinase
kinase (MKK1-SS/DD) or from T. MKK1-SS/DD cells recovered from
nude mice (19) were analyzed by Northern blot in comparison with
control cells (PS 200). Cells were serum-deprived for 16 h (–) and then
stimulated with 20% FCS for 3 h (1). RNA isolated from exponentially
growing normal cells were loaded as controls (CCL39, PS200/7.5%). The
blot was hybridized with probes corresponding to VEGF, VEGF-B, and
VEGF-C. Ethidium bromide coloration of 28 S ribosomal RNA is shown
as loading control. Probes used to specifically identify VEGF, VEGF-B,
and VEGF-C were as described under “Experimental Procedures.”
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examine the contribution of the Ras/p42/p44 MAP kinase path-
way in VEGF expression, we have chosen a cell line expressing
an estradiol-inducible Raf-1 (Raf-1:ER cells) (20–22). In this
case, the p42/p44 MAP kinase activity is rapidly activated by
estradiol, eliminating the contribution of SAP kinase cascade
(p38MAPK/JNK) (29, 30, 31) and phosphatidylinositol 3-kinase
cascade (32, 33) that are generally activated by serum or con-
stitutively active Ras. Raf-1:ER-expressing cells (see “Experi-
mental Procedures”) were serum-deprived for 16 h and then
stimulated by the addition of estradiol for the times indicated.
Fig. 2a shows that VEGF transcripts are expressed at a detect-
able level after 2 h and are maximally expressed after 3 h of
estradiol stimulation, the expression being sustained for up to
5 h. A longer exposure of the blot shows detectable transcripts
after only 30 min of stimulation (data not shown), and the
expression of the three other spliced variants are revealed in
Fig. 1. This rapid induction is compatible with the kinetics of
activation of p42/p44 MAP kinases in these cells (22). The
expression of VEGF-B and VEGF-C mRNA species are not
modified by estradiol treatment, confirming that activation of
the p42/p44 MAP kinase pathway does not play any role in
controlling their expression in these cells. Induction of VEGF
mRNA in response to estradiol was dose-dependent, with 70%
of the maximal induction obtained after a stimulation with 10
nM estradiol (Fig. 2b, lane 7), and maximal induction obtained
with 100 nM estradiol (Fig. 2b, lane 9). This dose-response
activity reflects the magnitude of activation of p42/p44 MAP
kinase in these cells (22). If the activity of MKK1, the kinase
directly downstream of Raf, is blocked by the specific inhibitor
PD 098059 (34) (Fig. 2c, lane 7), the p42/p44 MAP kinase
pathway-dependent induction of VEGF is inhibited by 50%
after 4 h of stimulation by estradiol (compare lanes 3 and 7 of
Fig. 2c). This result supports the hypothesis that the p42/p44
MAP kinase cascade plays a key role in VEGF gene induction.
The partial inhibition of MKK1 by PD 098059 (60–70% inhibi-
tion at this concentration)2 explains the residual VEGF mRNA
amount in Fig. 2c.
Additive Effect of Hypoxia and Growth Factors on VEGF
mRNA Induction—To test whether induction of VEGF mRNA
by hypoxia is dependent or not on the action of growth factors,
we submitted quiescent or exponentially growing CCL39 cells
to hypoxia for four hours. Fig. 3 shows that oxygen deprivation
on its own is able to induce VEGF mRNA induction in quies-
cent cells to a level that is comparable with the basal level
present in exponentially growing cells. When serum is present,
VEGF mRNA levels reached a level superior to that present in
quiescent cells following hypoxia. There is no discrepancy be-
tween the level observed in this experiment and the results
presented in Fig. 1. In Fig. 1, the blot was underexposed to
compare the high levels of mRNA in transformed cells. We
routinely observed a basal level of mRNA in exponentially
growing cells. However, the amounts of mRNA obtained after
serum stimulation of quiescent cells is at least five times more
elevated. Again, to analyze more directly the contribution of
p42/p44 MAP kinase, we used the Raf-1:ER cells stimulated by
estradiol in the presence or absence of oxygen (see Fig. 2b). At
suboptimal concentrations of estradiol (0.1 and 1 nM), which do
not maximally activate p42/p44 MAP kinase (22), we observed
the induction of VEGF by hypoxia. Estradiol and hypoxia exert
additive effects on VEGF mRNA induction at a dose of estradiol
(10 nM) that induces half of the p42/p44 MAP kinase activity
(see lane 8 of Fig. 2b). This situation is comparable with that
observed in Fig. 3 where exponentially growing cells are sub-
mitted to hypoxia. When a maximal dose of estradiol is used
(100 nM or 1 mM), a small additive effect with hypoxia persists,
but it is less detectable than that observed with 10 nM estradiol.
In the presence of PD 098059, the induction of VEGF mRNA by
hypoxia still occurs even if the estradiol-mediated induction of
VEGF mRNA is inhibited by 50% (see Fig. 2c). This result
suggests that the hypoxia-mediated VEGF mRNA increase is
independent of p42/p44 MAP kinase activity. This is further
emphasized by the fact that hypoxia is not capable of activating
p42/p44 MAP kinase activity in CCL39 cells (data not shown).
Expression of Constitutively Active Members of the p42/p44
MAP Kinase Pathway Increase VEGF Gene Transcription—To
assess the mechanism by which p42/p44 MAP kinase cascade
stimulates VEGF mRNA production, we directly analyzed the
activation of the VEGF promoter coupled to the luciferase
2 F. R. McKenzie, J. M. Brondello, and A. Brunet, unpublished
results.
FIG. 3. Hypoxia and growth factors have additive effects on
VEGF mRNA induction. Quiescent or exponentially growing CCL39
cells were submitted or not to hypoxia. 20 mg of RNA isolated from the
cells submitted to the different situations were analyzed by Northern
blot. 28 S ribosomal RNA is shown as loading control. FIG. 4. The p42/p44 MAP kinase pathway is required to up-
regulate VEGF gene transcription. 250 ng of different constructs of
the VEGF promoter (–1176/154; –88/154, –27/154) coupled to the
luciferase reporter gene were transfected together with 200 ng of empty
expression vector (Control) or 200 ng of expression vector coding for
constitutively active human Ras (Ras-Val12), constitutively active
MEK1 (MKK1-SS/DD), or p44 MAP kinase. In all cases, 100 ng of an
expression vector coding for b-galactosidase was co-transfected in order
to normalize for transfection efficiency. 24 h after transfection, cells
were serum-deprived for 20 h, and then luciferase activity was meas-
ured. When cells were transfected with p44 MAP kinase, they were also
stimulated with 10% FCS. The results shown correspond to four inde-
pendent experiments. Each set of data are the mean of triplicate
determinations.
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reporter gene as previously reported (15, 16, 35, 36). Fig. 4
shows that constitutively active Ras (Ras-Val12) or constitu-
tively active MKK1 (MKK1-SS/DD) can strongly stimulate the
VEGF promoter (–1176/154) in the absence of FCS when com-
pared with empty vector. Thus, both members of the p42/p44
MAP kinase pathway can stimulate VEGF gene transcription.
VEGF gene transcription is not significantly increased when a
p44 MAP kinase encoding construct is cotransfected with the
reporter vector in the absence of serum. However, when cells
are transfected with a p44 MAP kinase encoding construct in
the presence of serum, the level of transcription is significantly
increased when the –1176/154 and the –88/154 constructs are
used. VEGF promoter constructs (2888/154 (data not shown)
and –88/154) still conserved the capacity to be induced by
constitutively active Ras or MKK1 even if the response to
Ras-Val12 is reduced by 40% for the –88/154 construct and the
response to MKK1-SS/DD is not modified. This is surprising
since the –1176/–88 region contains putative AP-1 consensus
binding sites which are targets of transcription factors whose
activity is up-regulated by the p42/p44 MAP kinase pathway
(Jun/Fos). The difference observed between the stimulatory
effects of Ras and MKK1 is not attributable to the stress-
activated kinase pathways that are also activated by Ras be-
cause transfection of c-Jun N-terminal kinase (JNK) or p38/
HOG in the presence of activating agents (anisomycin, IL-1b)
or their constitutively active activating kinases (MKK3 or
MKK4) (31) has no effect on VEGF promoter activity (data not
shown). However, if AP-2 and Sp1 binding sites are deleted
(–27/154), the induction obtained with MKK1-SS/DD is totally
abrogated and the activation obtained with Ras-Val12 is inhib-
ited by 80%.
Characterization of the p42/p44 MAP Kinase Pathway Re-
sponsive Region of the VEGF Promoter—We next constructed
and analyzed the activities of the –66/154 and –52/154 con-
structs in comparison with the –1176, –88 and –27/154 con-
structs in the presence or absence of MKK1-SS/DD to localize
the p42/p44 MAP kinase pathway responsive element. Fig. 5
shows that while the –1176 and –88/154 constructs displayed
constitutive base-line activity, which was increased by cotrans-
fection with MKK1-SS/DD by a factor of 3.3 and 4.6, respec-
tively, analysis of the –66, –52, and –27/154 constructs showed
a loss of both basal and MKK 1 SS/DD transcriptional activa-
tion. These results suggest that sequences between –88 and
–66 are absolutely required for basal and p42/p44 MAP kinase-
dependent pathway-stimulated promoter activity. The loss of
both basal and stimulated transcriptional activity could reflect
a truncation of transcription factor binding sites in the –88/
154 construct that can regulate the overall activity of the
promoter.
Cooperative Effects of AP-2 and Sp1 in MKK1-SS/DD Stim-
ulation of VEGF Promoter—As shown by Gille et al. (37), TGF-
a-mediated induction of the VEGF promoter is a mechanism
involving the AP-2 transcription factor but not Egr-1, a mem-
ber of the same family. TGF-a acts via the EGF receptor whose
signaling is in part mediated by the p42/p44 MAP kinase path-
way (for reviews, see Refs. 38 and 39). Transfection of an
expression vector encoding AP-2 can stimulate the VEGF pro-
moter in CCL39 cells (data not shown), which is in agreement
with the data of Gille et al. (37). Based on these results, we
have investigated whether the p42/p44 MAP kinase pathway
induced VEGF mRNA levels by directly activating AP-2 or Sp1,
whose binding sites are present between –88 and –66. Fig. 6a
shows that within this region there exists two putative binding
sites for Sp1 and one for AP-2. These sites are conserved
between human, mouse, and rat promoters (35, 40–42). There-
fore, the intact –88/154 construct or a construction with point
mutations in the AP-2, both Sp1, or the three binding sites (Fig.
6a) were transfected in exponentially growing cells, and acti-
vation of the VEGF promoter was analyzed by luciferase assay.
FIG. 5. Identification of a p42/p44 MAP kinase pathway re-
sponsive region between –88 and –66 of the VEGF gene pro-
moter by 5* deletional analysis. CCL39 cells were transfected with
250 ng of the –88/154, –66/154, –52/154 and –27/154 in the presence
or absence of 200 ng of expression vector coding for constitutively active
MEK1 (MKK1-SS/DD). In all cases, 100 ng of an expression vector
coding for b-galactosidase was co-transfected in order to normalize for
transfection efficiency. 16 h after the transfection, the cells were rinsed
with PBS and grown in medium supplemented with 7.5% FCS for 48 h.
The cells were then lysed, and luciferase activity was measured. The
results correspond to three different experiments. Each set of data are
the mean of triplicate determinations.
FIG. 6. Cooperation of Sp1 and AP-2 for VEGF promoter acti-
vation. a, sequence of –88/–66 human VEGF promoter region. AP-2
binding site is boxed, and Sp1 binding sites are underlined. The muta-
tions for Sp1 or AP-2 binding sites are underlined. b, CCL39 cells were
transfected with 250 ng of the –88/154 promoter containing or not a
mutation for AP-2, both Sp1, or the three binding sites in the presence
or absence of 200 ng of expression vector coding for active MEK1
(MKK1-SS/DD). In all cases, 100 ng of an expression vector coding for
b-galactosidase was co-transfected in order to normalize for transfec-
tion efficiency. 16 h after the transfection, the cells were rinsed with
PBS and grown in medium supplemented with 7.5% FCS for 48 h. The
cells were then lysed, and luciferase activity was measured. The results
correspond to three different experiments. Each set of data are the
mean of triplicate determinations.
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The response to the p42/p44 MAP kinase module was assessed
by co-expression of constitutively active MKK1. Fig. 6b shows
that mutations of the AP-2 or both Sp1 putative binding sites
done individually do not significantly modify basal and MKK1-
SS/DD-stimulated promoter activity. However, a combined mu-
tation of AP-2 and both Sp1 binding sites dramatically de-
creases basal and MKK1-SS/DD-dependent transcriptional
activation. This result suggests a cooperative effect of AP-2 and
Sp1 for maximal transcriptional activation of the VEGF
promoter.
p42/p44 MAP Kinase Pathway Controls the Binding Activity
of Nuclear Protein Extracts to the 288/266 VEGF Promoter
Region in Raf-1:ER Cells—In order to confirm the specific role
of AP-2 and Sp1 transcription factors in the regulation of the
VEGF promoter, we utilized a double-stranded probe encom-
passing the –88/–66-bp region in EMSA experiments. Fig. 7
shows four constitutive DNA binding complexes in resting or in
estradiol-stimulated Raf-1:ER cells (complexes a, B, c, D; see
lanes 1 and 6 of Fig. 7b). To demonstrate that either Sp1 or
AP-2 are present in at least the large complex B, we performed
supershift experiments. Indeed, Sp1 antibodies supershifted
part of complex B formed with extracts from resting cells (data
not shown) or estradiol-stimulated cells (Fig. 7a, left, compare
lanes 1 and 2). Similarly, AP-2 antibodies supershifted part of
complex B with extracts from estradiol-stimulated cells (Fig.
7a, right, compare lanes 2 and 3). This supershift, however, is
more evident in the presence of Sp1 neutralizing oligonucleo-
tides. The binding specificity of the complexes formed were
determined by exclusive competition with an excess of identical
unlabeled DNA (Fig. 7b). Under resting conditions, DNA bind-
ing of complexes a, B, and c are clearly inhibited by either Sp1
or AP-2-specific oligonucleotides (Fig. 7b, compare lane 1 or 5
with lanes 3 and 4). However, a remarkable change is observed
when p42/p44 MAP kinase was specifically stimulated with
estradiol. Nuclear extracts of cells stimulated for 3 h with
estradiol show a strong increase in the binding of complex B.
This is seen in Fig. 7b, right panel, where complex B is better
resolved and enlarged. Another striking change occurs when
binding is inhibited with a 100-fold excess of Sp1 oligonucleo-
tides (Fig. 7b, compare lanes 3 and 8). Under stimulated con-
ditions, complex B resists the competition with the Sp1 oligo-
nucleotides, reflecting that more proteins are bound and/or
have a higher affinity. The same result is observed when AP-2
oligonucleotides are used as a competitor, even if in this case
the labeling of the resistant complex B is less intense. Alto-
gether, these data clearly demonstrate that Sp1 and AP-2
transcription factors bind to the –88/–66 region of the VEGF
promoter and that p42/p44 MAP kinase activity plays a key
role in controlling the VEGF promoter activity via these sites.
DISCUSSION
The expression level of the VEGF mRNA is tightly regulated
by both transcriptional and post-transcriptional mechanisms
(15–17, 35, 43). A variety of cytokines and growth factors,
including epidermal growth factor, transforming growth factor
a, transforming growth factor b, interleukins 1 and 6 (44–47),
as well as transforming agents such as v-Ha-Ras and v-Raf (14)
were shown to induce VEGF expression in several cell lines,
and Pedram et al. (48) have proposed a role for Erk in the
endothelin activation of the VEGF promoter. However, the
signaling cascades involved have not been fully deciphered.
Here, we have analyzed VEGF, VEGF-B (24), and VEGF-C (25)
expression in quiescent, serum-stimulated, or oncogenically
transformed CCL39 cells. In all the conditions where p42/p44
MAP kinase activity is strongly enhanced, the VEGF mRNA
levels are especially increased; this is particularly notable in
Ras-Val12 or MKK1-SS/DD transformed cells. This first result
suggests that regulation of VEGF gene expression occurs
through a p42/p44 MAP kinase-dependent mechanism. To con-
firm more directly the role of the p42/p44 MAP kinase pathway
in this mechanism, we have used a cell line where p42/p44
MAP kinase activity is tightly regulated by an estradiol-induc-
ible Raf-1 (Raf-1:ER). The stimulation of p42/p44 MAP kinase
cascade via the estradiol-dependent Raf activity eliminates the
contribution of alternative signaling cascades such as stress-
activated protein kinases (p38 HOG/JNK) or phosphatidyli-
FIG. 7. Identification of AP-2 and Sp1 transcription factors in
the p42/p44 MAP kinase pathway-inducible DNA binding com-
plex. Panel a, left, EMSAs with nuclear extracts of estradiol-stimulated
Raf-1:ER cells (lanes 1 and 2) in the absence (lane 1) or the presence
(lane 2) of Sp1-specific antibodies (0.2 mg). Panel a, right, EMSAs with
nuclear extracts of estradiol-stimulated Raf-1:ER cells in the absence
(lane 1) or the presence (lanes 2 and 3) of unlabeled doubled-stranded
Sp1 oligonucleotides and in the absence (lanes 1 and 2) or the presence
(lane 3) of AP-2 specific antibodies (1 mg). The different complexes
observed (a, B) are shown by arrows. Panel b, EMSAs with nuclear
extracts of untreated (lanes 1 to 5) or estradiol-stimulated (lanes 6 to 10)
Raf-1:ER cells in the absence (lanes 1, 5, 6, and 10) or the presence of
excess unlabeled probe (lanes 2 and 7), or excess of double-stranded Sp1
consensus oligonucleotides (lanes 3 and 8), or excess of doubled-
stranded AP-2 consensus oligonucleotides (lanes 4 and 9). Formation of
specific complexes is indicated on the left (a, B, c, and D). The DNA
sequence of the probe used is indicated under “Experimental Proce-
dures.” Competitor was used at a concentration of 100 molar excess. An
enlargement of complexes a and B upon resting or stimulated condi-
tions is shown on the right of the figure.
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nositol 3-kinase activated by serum or oncogenic Ras. Hence,
production of VEGF mRNA is stimulated by estradiol in a time-
and a dose-dependent manner. Furthermore, utilization of the
MKK1 inhibitor PD 098059 (34) in Raf-1:ER cells after a max-
imal activation of p42/p44 MAP kinase confirmed the impor-
tance of the p42/p44 MAP kinase pathway in VEGF gene in-
duction by growth factors. Also notable is that the two new
VEGF-related mRNAs, VEGF-B and VEGF-C, show a different
mode of regulation. Their mRNA levels do not vary or do not
present the same spectacular induction in the transformed
cells tested and are not regulated by estradiol stimulation in
Raf-1:ER cells (compare Figs. 1 and 2a). A possible interpreta-
tion of this data is that the cellular system investigated is not
appropriate for testing the fine regulation of both genes. En-
holm et al. (49) have observed an induction of VEGF and
VEGF-C in IMR-90 cells by serum, PDGF, EGF, and TGF-b but
no regulation of VEGF-B after such stimulations, which is in
favor of a specific cell context for such an induction.
We then analyzed the contribution of members of the p42/
p44 MAP kinase module on VEGF transcription. The human,
the mouse, and the rat VEGF promoter contains binding sites
for AP-2, Sp1, or Sp1-related factors (35, 40–42, 50) in addition
to binding sites for AP-1 (51) and HIF-1 (16, 35), which regulate
the transcription of the gene during hypoxia (43). The mouse
VEGF promoter also contains additional NFkB binding sites
(42). A recent report by Gille et al. (37) described the AP-2
transcription factor as the major factor implicated in the TGF-a
stimulation of VEGF gene transcription in A431 cells. They
also showed that Sp1 is constitutively bound to the promoter
(37). However, the promoter region responsible for such a reg-
ulation can bind AP-2 as well as Egr-1, but AP-2 only regulates
the promoter activity. Furthermore, they showed that pro-
moter activity still remains even after AP-2 binding site muta-
tion but is reduced by 50%. In the present study, we have
dissected the events responsible for the increase of VEGF tran-
scription. The proximal promoter elements contained within
construct –88/154 were found to be sufficient to drive the
stimulation of transcription induced by p42/p44 MAP kinase
activation. Interestingly, the –88/154 construct can still be
activated by Ras-Val12 and MKK1-SS/DD. This is surprising
since the region comprised between –1176 and –88 contains a
consensus AP-1 binding site that is regulated via the p42/p44
MAP kinase module. However, mutations on the AP-2 or Sp1
binding sites, and in particular mutations in the three binding
sites, strongly reduced basal and MKK1-SS/DD-stimulated
VEGF promoter transcription. This is in accord with the results
of Gille et al. (37) who showed that even if the AP-2 binding site
is mutated, the promoter still displays high basal activity,
possibly driven through Sp1 binding.
We have further analyzed the –88/–66 region by EMSA as
well as supershift experiments. We observed four major DNA-
proteins complexes either with extracts from stimulated or
unstimulated Raf-1:ER cells. With the use of specific antibod-
ies, we confirmed that AP-2 and Sp1 are components of the
more intense complex B. This fundamental role of Sp1 is in
agreement with the results of Yoshida et al. (52) who have
shown that Sp1 is required for the stimulation of VEGF tran-
scription by TNF-a and that antisense oligo-nucleotides can
partially inhibit the TNF-a-dependent production of VEGF. We
also show a spectacular increase in the labeling of part of
complex B upon estradiol stimulation, which is resistant to
competition with Sp1 oligonucleotides. Part of complex B is also
enhanced upon estradiol stimulation when AP-2 competitor
oligonucleotides are used. This result confirmed that activation
of p42/p44 MAP kinase activation has a direct effect on AP-2
and Sp1. We are presently investigating whether this effect is
mediated through an increase in binding affinity which could
be regulated by phosphorylation or mediated by an increase in
the amounts of both factors. However, we cannot exclude that
p42/p44 MAP kinase may activate other transcription factors
that could be components of the B complex. Egr-1 is a good
candidate for such a regulation even if it has been shown that
the transfection of an Egr-1 encoding construct has no effect on
the VEGF promoter activity (37). We also observed two other
complexes in EMSAs (a and c) that are inhibited by an excess
of cold Sp1 or AP-2 oligonucleotides. While complex a is en-
hanced by estradiol treatment, complex c is not affected. Com-
plex a could be the result of an association between Sp1 and
AP-2. Complex c could be the result of Sp1 (41, 53) or AP-2-
related factors binding (54, 55). This is in agreement with
previous results which have shown that Egr-1 can bind to this
region of the promoter (37).
Another interesting feature of VEGF regulation is its strong
up-regulation upon oxygen deprivation by both transcriptional
induction and stabilization of the mRNA by interaction of pro-
teins with the 39-untranslated region (15–17, 35, 43). Mukho-
padhyay et al. have shown that hypoxic induction of VEGF is
blocked by genistein and that c-Src is implicated in such an
activation. They also showed that the dominant negative form
of c-Src or Raf-1 can block hypoxic induction of VEGF (56). In
our cell system, we show that such an induction is totally
independent on growth factor action but that a combination of
growth factor stimulation and oxygen deprivation have addi-
tive effects on VEGF mRNA induction. In Raf-1:ER cells, the
inhibition of p42/p44 MAP kinase pathway by PD 098059 does
not affect induction of VEGF by hypoxia (Fig. 2c), confirming
that the induction of VEGF mRNA strictly attributable to
p42/p44 MAP kinase activation and induction of VEGF by
hypoxia are two independent mechanisms. There is no discrep-
ancy between our results and those of Mukhopadhyay et al. (56)
since Raf-1 can signal independently of Erk (22, 33), and dom-
inant negative forms of Raf-1 can also titrate signals emerging
from Ras which then activate independent pathways (32, 33).
Our results have a strong physiological implication. The role of
Ras oncogenes in the pathogenesis of human cancers is well
established. Here we show that one of the target genes of the
p42/p44 MAP kinase pathway which is activated by Ras is
VEGF. As tumors are known to secrete growth factors activat-
ing the p42/p44 MAP kinase pathway such as FGF or relatives
(3, 4, 57), VEGF expression initiated at least by constitutively
active members of the p42/p44 MAP kinase pathway is ampli-
fied by a paracrine mechanism via the same transduction path-
way. Such a regulation is strictly transcriptional and depends
on activation of the VEGF promoter through at least two tran-
scription factors, AP-2 and Sp1. We also show that growth
factors and oxygen deprivation have additive effects which
contribute to the increase of VEGF expression. We are now
deciphering how the signal mediated by oxygen deprivation is
sensed by the cells and which transduction pathways are im-
plicated in VEGF induction.
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